Phase i study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers

Keyphrases

• Innate Immune Response 100%
• Phase I Study 100%
• Gynecological Cancer 100%
• Immune Regulation 100%
• Carbohydrate Antigen 125 (CA125) 100%
• Pharmacology 100%
• Interleukin-12 (IL-12) 66%
• CA-125 Levels 66%
• Immunostimulator 66%
• High Dose 33%
• In Vitro Activity 33%
• Chemotherapy 33%
• Treatment Dose 33%
• Protein Drug 33%
• Clinical Setting 33%
• Recombinant Protein 33%
• Plasma Parameters 33%
• Pharmacodynamic Markers 33%
• Gynecologic Malignancies 33%
• Multiple Dose 33%
• % Response 33%
• Heavily Pretreated 33%
• Primary Peritoneal Cancer 33%
• Adverse Reactions 33%
• Dose-ranging 33%
• Inter-patient Variability 33%
• Intra-patient 33%
• Eimeria 33%
• Primary Endometrial Cancer 33%
• Phase I Trial 33%
• Accelerated Phase 33%
• Start of Treatment 33%
• Safety Pharmacology 33%
• Basic Pharmacology 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Female Genital Tract Cancer 100%
• Protozoon 100%
• Interleukin 12 100%
• Adverse Event 50%
• Biological Marker 50%
• Pharmacodynamics 50%
• Chemotherapy 50%
• Endometrium Cancer 50%
• Recombinant Protein 50%
• Peritoneum Cancer 50%
• Phase I Trials 50%
• Eimeria 50%

Medicine and Dentistry

• Female Genital Tract Cancer 100%
• CA-125 100%
• Innate Immune Modulator 100%
• Interleukin 12 40%
• Biological Marker 20%
• In Vitro 20%
• Adverse Event 20%
• Cancer 20%
• Drug Megadose 20%
• Low Drug Dose 20%
• Pharmacodynamics 20%
• Protozoa 20%
• Uterine Cancer 20%
• Recombinant Protein 20%
• Phase I Trials 20%
• Eimeria 20%
• Peritoneum Cancer 20%